AstraZeneca PLC (AZN)
184.49
+0.11
(+0.06%)
USD |
NYSE |
Nov 13, 16:00
188.13
+3.64
(+1.97%)
After-Hours: 18:16
AstraZeneca Enterprise Value : 598.18B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 598.18B |
| November 11, 2026 | 601.59B |
| November 10, 2026 | 605.56B |
| November 09, 2026 | 613.72B |
| November 06, 2026 | 604.54B |
| November 05, 2026 | 605.84B |
| November 04, 2026 | 612.54B |
| November 03, 2026 | 596.63B |
| November 02, 2026 | 605.00B |
| October 30, 2026 | 605.22B |
| October 29, 2026 | 567.22B |
| October 28, 2026 | 552.06B |
| October 27, 2026 | 553.83B |
| October 26, 2026 | 559.97B |
| October 23, 2026 | 558.20B |
| October 22, 2026 | 561.55B |
| October 21, 2026 | 548.77B |
| October 20, 2026 | 549.92B |
| October 19, 2026 | 534.81B |
| October 16, 2026 | 539.34B |
| October 15, 2026 | 543.28B |
| October 14, 2026 | 528.86B |
| October 13, 2026 | 509.60B |
| October 12, 2026 | 517.38B |
| October 09, 2026 | 520.08B |
| Date | Value |
|---|---|
| October 08, 2026 | 518.78B |
| October 07, 2026 | 522.93B |
| October 06, 2026 | 518.25B |
| October 05, 2026 | 511.80B |
| October 02, 2026 | 512.95B |
| October 01, 2026 | 515.43B |
| September 30, 2026 | 527.12B |
| September 29, 2026 | 535.62B |
| September 28, 2026 | 541.64B |
| September 25, 2026 | 542.97B |
| September 24, 2026 | 536.70B |
| September 23, 2026 | 532.89B |
| September 22, 2026 | 548.52B |
| September 21, 2026 | 547.68B |
| September 18, 2026 | 541.42B |
| September 17, 2026 | 541.60B |
| September 16, 2026 | 531.52B |
| September 15, 2026 | 528.30B |
| September 14, 2026 | 534.29B |
| September 11, 2026 | 523.09B |
| September 10, 2026 | 521.44B |
| September 09, 2026 | 513.07B |
| September 08, 2026 | 522.68B |
| September 04, 2026 | 530.94B |
| September 03, 2026 | 537.36B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| GSK Plc | 128.54B |
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
| Merck & Co., Inc. | 406.57B |
| Novo Nordisk A/S | 149.40B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.076B |
| Revenue (Quarterly) | 15.26B |
| Total Expenses (Quarterly) | 12.19B |
| EPS Diluted (Quarterly) | 0.9849 |
| Gross Profit Margin (Quarterly) | 76.09% |
| Profit Margin (Quarterly) | 20.15% |
| Earnings Yield | 1.80% |
| Operating Earnings Yield | 2.44% |
| Normalized Earnings Yield | 1.826 |